Chemical heterogeneity of [3H]imipramine binding sites on human platelet membranes. 1990

A M Fomenko, and Y G Plyashkevich, and O S Brusov, and V P Demushkin
Laboratory of Neurochemistry, All-Union Research Centre for Mental Health, Acad. Med. Sci. U.S.S.R., Moscow.

Functional groups essential for high- and low-affinity [3H]imipramine (IMI) binding were determined by the method of chemical modification. The high-affinity recognition sites contained cysteine and lysine amino acid residues, but not aspartic or glutamic acid residues. The low-affinity recognition sites contained only cysteine residues. Moreover, probably only part of these sites contained these residues. The arginine, tyrosine and histidine residues are not likely to be functionally important for the [3H]IMI binding process. Analysis of the structure-function interaction of drug molecules reveals that, for all substances with high displacement ability, there is a conformation in which they can react with high-affinity IMI recognition sites. Data obtained allowed us to construct a tentative structure model of the high-affinity recognition IMI binding site.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008961 Models, Structural A representation, generally small in scale, to show the structure, construction, or appearance of something. (From Random House Unabridged Dictionary, 2d ed) Model, Structural,Structural Model,Structural Models
D011619 Psychotropic Drugs A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). Psychoactive Agent,Psychoactive Agents,Psychoactive Drug,Psychopharmaceutical,Psychopharmaceuticals,Psychotropic Drug,Psychoactive Drugs,Agent, Psychoactive,Agents, Psychoactive,Drug, Psychoactive,Drug, Psychotropic,Drugs, Psychoactive,Drugs, Psychotropic
D011955 Receptors, Drug Proteins that bind specific drugs with high affinity and trigger intracellular changes influencing the behavior of cells. Drug receptors are generally thought to be receptors for some endogenous substance not otherwise specified. Drug Receptors,Drug Receptor,Receptor, Drug
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D002352 Carrier Proteins Proteins that bind or transport specific substances in the blood, within the cell, or across cell membranes. Binding Proteins,Carrier Protein,Transport Protein,Transport Proteins,Binding Protein,Protein, Carrier,Proteins, Carrier
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D002540 Cerebral Cortex The thin layer of GRAY MATTER on the surface of the CEREBRAL HEMISPHERES that develops from the TELENCEPHALON and folds into gyri and sulci. It reaches its highest development in humans and is responsible for intellectual faculties and higher mental functions. Allocortex,Archipallium,Cortex Cerebri,Cortical Plate,Paleocortex,Periallocortex,Allocortices,Archipalliums,Cerebral Cortices,Cortex Cerebrus,Cortex, Cerebral,Cortical Plates,Paleocortices,Periallocortices,Plate, Cortical
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006863 Hydrogen-Ion Concentration The normality of a solution with respect to HYDROGEN ions; H+. It is related to acidity measurements in most cases by pH pH,Concentration, Hydrogen-Ion,Concentrations, Hydrogen-Ion,Hydrogen Ion Concentration,Hydrogen-Ion Concentrations

Related Publications

A M Fomenko, and Y G Plyashkevich, and O S Brusov, and V P Demushkin
April 1984, European journal of pharmacology,
A M Fomenko, and Y G Plyashkevich, and O S Brusov, and V P Demushkin
December 1990, Psychiatry research,
A M Fomenko, and Y G Plyashkevich, and O S Brusov, and V P Demushkin
July 1986, European journal of pharmacology,
A M Fomenko, and Y G Plyashkevich, and O S Brusov, and V P Demushkin
December 1983, European journal of pharmacology,
A M Fomenko, and Y G Plyashkevich, and O S Brusov, and V P Demushkin
December 1983, Biological psychiatry,
A M Fomenko, and Y G Plyashkevich, and O S Brusov, and V P Demushkin
January 1987, Progress in clinical and biological research,
A M Fomenko, and Y G Plyashkevich, and O S Brusov, and V P Demushkin
July 1984, Journal of neurology, neurosurgery, and psychiatry,
A M Fomenko, and Y G Plyashkevich, and O S Brusov, and V P Demushkin
September 1991, Biological psychiatry,
A M Fomenko, and Y G Plyashkevich, and O S Brusov, and V P Demushkin
November 1984, European journal of pharmacology,
A M Fomenko, and Y G Plyashkevich, and O S Brusov, and V P Demushkin
October 1985, Psychiatry research,
Copied contents to your clipboard!